Skip to Main Content

Paper Details

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Cancer Discov
144
2019
Author NameAffiliation
Sunil SharmaHuntsman Cancer Institute
Nicolas StranskyBlueprint Medicines Corporation
  • 1 - 2

Datasets

Release 1.2